App-Quantinova.ai

Impaired Satiety Effect of GLP-1 Agonist in Obesity Is Associated With GLP-1 Resistance in Intestinal Afferent Nerves

Beini Wang - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Exenatide

Faecalibacterium prausnitzii Prevents Irritable Bowel Syndrome-Like Symptoms in Both Murine Low Grade Chronic Inflammation and Acute Stress Models

Sylvie Miquel - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

IL-4

The Adoptive Transfer of Anxiety and Gut Dysfunction From IBS Patients to Axenic Mice Through Microbiota Transplantation

Michael D. Lynch - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Is Small Intestinal Bacterial Overgrowth Common in Chronic Pancreatitis?

Simon Bouchard - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hereditary pancreatitis

Kristalose Oral

in Functional Dyspepsia, Are Meal-Related Symptoms Linked to Less Drinking Capacity?

Yuri A. Saito - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Functional Dyspepsia

N/A

Patients With Active Celiac Disease Have Altered Intercellular Spaces and Tight Junction Structure of the Lower Esophagus That May Explain the High Prevalence of Reflux Symptoms in These Patients

Salma Salim - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastroesophageal reflux disease

N/A

MiR-142-3p Directly Regulates Autophagy-Dependent Gene ATG16L1 in Crohn's Disease

David M. Rodrigues - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Inflammatory bowel disease

N/A

Investigating the Microbiome Pre and Post Fecal Microbiota Therapy From Active Ulcerative Colitis Patients in a Randomized Placebo Controlled Trial

Fiona J. Whelan - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Roseduria hominis

Turquoise-II: Svr12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults With Compensated Cirrhosis Treated With ABT-450/r/ABT-267 and ABT-333 Plus Ribavirin (3D+RBV)

Fred Poordad - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatitis C

Alfa-fetoprotein

Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I

Srdan Verstovsek - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria

Richard A. Wells - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Erythropoietin

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Peter Duggan - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Sam Scanga - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

Lenalidomide

Niche Requirements of Transient Leukemia Cells in Down Syndrome

Jian Chen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute myelocytic leukemia

N/A

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Francesco Merli - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Rituximab

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Anas Younes - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

L-Tyrosine

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Kiyohiko Hatake - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

Filgrastim

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Valeria Buccheri - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Lymphocytic Leukemia

Cyclophosphamide

Identification of a Unique Autophagy Gene Expression Signature in CD34+ CML Stem/Progenitor Cells That Correlates with Clinical Response to Imatinib Mesylate

Kevin B.L. Lin - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells

David P. Sheridan - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Doxycycline

Filters

28841 Abstracts